Literature DB >> 34532509

Expression and Ni-NTA-Agarose Purification of Recombinant Hepatitis C Virus E2Ectodomain Produced in a Baculovirus Expression System.

Julián Gómez-Gutiérrez1, Mar Rodríguez-Rodríguez1, Francisco Gavilanes1, Belén Yélamos1.   

Abstract

In this protocol, we describe the production and purification of the ectodomain of the E2661 envelope protein (amino acids 384-661) of the Hepatitis C virus, which plays a fundamental role in the entry of the virus into the host cell. This protein has been expressed in both prokaryotic and eukaryotic systems but in small quantities or without native protein characteristics. In our case, we use the Baculovirus expression system in insect cells. E2661 is secreted into the extracellular medium and purified by means of affinity chromatography a Ni-NTA-column because the protein has a tag of six histidines at its amino terminal end. The purified protein possesses a native-like conformation and it is produced in large quantities, around 5-6 mg per liter.
Copyright © 2018 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Affinity chromatography; Baculovirus expression system; Ectodomain; Envelope protein; Hepatitis C virus; Recombinant proteins

Year:  2018        PMID: 34532509      PMCID: PMC8342046          DOI: 10.21769/BioProtoc.3030

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  5 in total

Review 1.  Viral hepatitis.

Authors:  Harvey Alter
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

2.  Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein.

Authors:  M Flint; J Dubuisson; C Maidens; R Harrop; G R Guile; P Borrow; J A McKeating
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 3.  Treatment of hepatitis C: a systematic review.

Authors:  Anita Kohli; Ashton Shaffer; Amy Sherman; Shyam Kottilil
Journal:  JAMA       Date:  2014-08-13       Impact factor: 56.272

4.  Structural properties of the ectodomain of hepatitis C virus E2 envelope protein.

Authors:  Mar Rodríguez-Rodríguez; Daniel Tello; Belén Yélamos; Julián Gómez-Gutiérrez; Beatriz Pacheco; Sara Ortega; Alicia G Serrano; Darrell L Peterson; Francisco Gavilanes
Journal:  Virus Res       Date:  2008-12-06       Impact factor: 3.303

Review 5.  Current and future therapies for hepatitis C virus infection: from viral proteins to host targets.

Authors:  Muhammad Imran; Sobia Manzoor; Nasir Mahmood Khattak; Madiha Khalid; Qazi Laeeque Ahmed; Fahed Parvaiz; Muqddas Tariq; Javed Ashraf; Waseem Ashraf; Sikandar Azam; Muhammad Ashraf
Journal:  Arch Virol       Date:  2013-08-25       Impact factor: 2.574

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.